Barclays
CCEL icon

Barclays’s Cryo-Cell International CCEL Stock Holding History

Barclays’s Portfolio CCEL Stock Details CCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45 Buy
+14
New +$50 ﹤0.01% 5247

Other funds holding CCEL

SA
SFI Advisors Montclair, New Jersey $116M AUM 37.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Barclays's CCEL Position: Q2 2026 in Review

Barclays opened a new position in Cryo-Cell International (CCEL) in Q2 2026: 14 shares worth $45. The stake represents ﹤0.01% of the portfolio and ranks #5247 among its holdings.

12 funds tracked by Wall St. Rank hold CCEL as of Q2 2026.

  • Barclays held 14 shares of Cryo-Cell International worth $45 as of Q2 2026.
  • Cryo-Cell International was a new Barclays position in Q2 2026.
  • Cryo-Cell International made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5247 holding.
  • 12 funds tracked by Wall St. Rank held Cryo-Cell International as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.